Intellia Therapeutics Inc

NTLA remains in a Stage 4 decline with confirmed downtrend and a Bearish Pivot Point signaling structural repair. The medium-term bias is bearish, prohibiting long entries and prioritizing sell-side engagement. Short-term timing is unfavorable due to oversold extension below down-sloping EMAs, so execution should wait for shallow rallies into the 9/21 EMA and 50-day SMA cluster for rejection.

• ↑Phase 3 LOMVOSI shows 87% attack reduction vs placebo.
• ↑$630.5M cash balance funds operations into mid-2027.
• ↓FDA clinical hold on NEXE program disrupts enrollment timelines.